Inflammatory Breast Cancer Clinical Trial
Official title:
A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Verified date | July 2017 |
Source | German Breast Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Two regimen are currently considered to have highest efficacy for patients with high-risk
early stage breast cancer: sequential treatment of high dose epirubicin, taxane, and
cyclophosphamide concomitantly with a dual HER2-blockade, and weekly treatment with
paclitaxel/non-pegylated liposomal doxorubicin with dual HER2-blockade or carboplatin. The
aim of the GeparOcto study is to compare those two regimen/strategies.
Both regimens are myelosuppressive with a significant incidence of chemotherapy induced
anaemia.
The second aim of the GeparOcto study is therefore to compare the use of parental ferric
carboxymaltose versus physician's choice for the treatment of chemotherapy-induced anemia in
patients with iron deficiency.
Status | Completed |
Enrollment | 961 |
Est. completion date | January 30, 2017 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients will be eligible for study participation only if they comply with the following criteria: - Written informed consent according to local regulatory requirements prior to beginning specific protocol procedures. - Complete baseline documentation must be submitted via MedCODES to GBG Forschungs GmbH. - Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration from the breast lesion alone is not sufficient. Incisional biopsy or axillary clearance is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint. - Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion. - Patients must have stage cT1c - cT4a-d disease. Patients with HER2- positive or TNBC are eligible irrespective of nodal status (cN0-cN3). Patients with luminal B-like tumors (defined here as ER and/or PgR >1% stained cells, HER2 negative, Ki-67 >20%) only with histologically (sentinel-node biopsy, core- or fine-needle biopsy) involved lymph nodes (pN1-3). - In patients with multifocal or multicentric breast cancer, the largest lesion should be measured. - Centrally confirmed ER, PR and HER2 status. Central pathology includes also assessment of Ki-67 and LPBC status on core biopsy. ER/PR negative is defined as <=1% stained cells and HER2-positive is defined as IHC 3+ or in-situ hybridization (ISH) and according to ASCO-CAP guidelines as of 2013). Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the GBG central pathology laboratory prior to randomization. - Age >=18 years. - Karnofsky Performance status index 90%. - Confirmed normal cardiac function by ECG and cardiac ultrasound (LVEF or shortening fraction) within 4 weeks prior to randomization. LVEF must be above 55%. - Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of childbearing potential. - Complete staging work-up within 3 months prior to randomization. All patients must have bilateral mammography, breast ultrasound (21 days), breast MRI (optional). Chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan in case of high risk for primary metastasis. In case of a positive bone scan, bone X-ray or CT scan is mandatory. Other tests may be performed as clinically indicated. - Patients must agree with central pathology testing of core biopsy specimen and final pathology specimen and be available and compliant for treatment and follow-up. - In addition for patients to be randomized to the two supportive anemia treatment arms: - Hemoglobin level <10g/dl. - Body weight = 40 kg. - No need for immediate red blood cell transfusion. - Transferrin saturation (TSAT) =20% and serum ferritin <300ng/ml. Exclusion Criteria: - Patients with ER- and/or PR-positive, HER2-negative breast cancer and Ki- 67 <= 20% (any luminal A-like subtype) or luminal B-like (Ki67>20%) subtype without nodal involvement. - Patients with stages cT1a, cT1b, or any M1. - Patients with pure lobular invasive breast cancer. - Prior chemotherapy for any malignancy. - Prior radiation therapy for breast cancer. - Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization) during study treatment. - Inadequate general condition (not fit for dose-dense, dose-intensified anthracycline-taxane-targeted agents-based chemotherapy). - Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer). - Known or suspected congestive heart failure (>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP >140/90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease. - History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent. - Pre-existing motor or sensory neuropathy of a severity grade 2 by NCI-CTC criteria v 4.0. - Currently active infection. - Incomplete wound healing. - Definite contraindications for the use of corticosteroids. - Known hypersensitivity reaction to one of the compounds or incorporated substances used in this protocol. - Concurrent treatment with: - chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (10 mg or less methylprednisolone or equivalent). - sex hormones. Prior treatment must be stopped before study entry. - other experimental drugs or any other anti-cancer therapy. - Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry. - Male patients. In addition for patients to be randomized to the two supportive anemia treatment arms: - Iron substitution (oral or IV) or blood transfusions or treatment with r-HuEPO with the last 4 weeks prior to study start. - Known hypersensibility or contraindication against ferric carboxymaltose. |
Country | Name | City | State |
---|---|---|---|
Germany | NTC | Heidelberg | Baden-Württemberg |
Lead Sponsor | Collaborator |
---|---|
German Breast Group | Amgen, Roche Pharma AG, TEVA, Vifor Pharma |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pathological complete response (pCR= ypT0/is ypN0) | To compare the pathological complete response (pCR= ypT0/is ypN0) rates of neoadjuvant treatment with sequential, dose-dense, dose-intensified ETC(+HP) vs. weekly PM(Cb)(+HP) in patients with high-risk operable or locally advanced breast cancer. Masked role for assessor. |
18 weeks (time window + 3 weeks) | |
Primary | Only for those patients randomized for the supportive anemia treatment: frequency of patients reaching hemoglobin (Hb) levels = 11g/dl 6 weeks after treatment start of a first episode of anemia grade =2 | Only for those patients randomized for the supportive anemia treatment: To compare the frequency of patients reaching hemoglobin (Hb) levels = 11g/dl 6 weeks after treatment start of a first episode of anemia grade =2 (Hb < 10g/dl) between patients receiving supportive treatment for iron deficiency with parental ferric carboxymaltose versus physician's choice (no supportive treatment, oral iron substitution, erythropoiesis-stimulating agent (ESA), or both). |
18 weeks (time window + 3 weeks) | |
Secondary | pcR rates per arm | To assess the pCR rates per arm separately for the stratified subpopulations. | 18 weeks (time frame + 3 weeks) | |
Secondary | Clinical and imaging response | To determine the response rates of the breast tumor and axillary nodes based on physical examination and imaging tests (sonography, mammography, or MRI) after treatment in both arms. | 18 weeks (time window + 3 weeks) | |
Secondary | Rates of ypT0 ypN0; ypT0 ypN0/+; ypT0/is ypN0/+; ypT(any) ypN0; and the residual cancer burden (RCB) score. | Response (by physical examination, imaging response, breast conservation) will also be summarized as rates in each treatment group). | 18 weeks (time frame + 3 weeks) | |
Secondary | Toxicity and Compliance including incidence of febrile neutropenia | Descriptive statistics for the 5 treatments (ETC +/- anti-HER2-treatment, PM +/- anti-HER2-treatment, PMCb) will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped. | 18 weeks (time frame + 3 weeks) | |
Secondary | Breast conservation rate | To determine the breast conservation rate after each treatment. | 18 weeks (time frame: + 3 weeks) | |
Secondary | loco-regional invasive recurrence free survival (LRRFS) in both arms and according to stratified subpopulations | LRRFS is defined as the time period between registration and first event and will be analyzed after the end of the study by referring to data from GBG patient's registry. | 5 years | |
Secondary | distant-disease-free survival (DDFS) in both arms and according to stratified subpopulations. | DDFS is defined as the time period between registration and first event and will be analyzed after the end of the study by referring to data from GBG patient's registry. | 5 years | |
Secondary | invasive disease-free survival (IDFS) in both arms and according to stratified subpopulations. | IDFS is defined as the time period between registration and first event and will be analyzed after the end of the study by referring to data from GBG patient's registry. | 5 years | |
Secondary | overall survival (OS) in both arms and according to stratified subpopulations. | OS is defined as the time period between registration and first event and will be analyzed after the end of the study by referring to data from GBG patient's registry. | 5 years | |
Secondary | regional recurrence free survival (RRFS) in patients with initial node-positive axilla | To assess regional recurrence free survival (RRFS) in patients with initial node-positive axilla converted to negative (ypN0) at surgery and treated with sentinel node biopsy alone. | until event occurs - no event for cured patients | |
Secondary | pCR rate and local recurrence free survival (LRFS) in patients with a clinical complete response (cCR) and a negative core biopsy | To determine the pCR rate and local recurrence free survival (LRFS) in patients with a clinical complete response (cCR) and a negative core biopsy before surgery. | 5 years | |
Secondary | Correlation of response | To correlate response (complete vs. partial vs. no change) measured by best appropriate imaging method after 6 weeks of treatment with pCR. | 18 weeks (time frame + 3 weeks) | |
Secondary | Examination and comparison of molecular markers | To examine and compare pre-specified molecular and histological markers such as Ki67, stromal TILs, immunologically relevant genes (e.g. CXCL9, CCL5, CD8A, CD80, CXCL13, IGKC, CD21, IDO1, PD-1, PDL1, CTLA4, FOXP3, and combinations of these genes) as well as e.g. CD138, CD47, MET and other markers on core biopsies before and eventually also on surgical tissue after end of chemotherapy. The aim is to identify potential predictive short and long term parameters. |
Baseline and 18 weeks (time frame + 3 weeks) | |
Secondary | Examination of PIK3CA mutation | To examine PIK3CA mutation in patients with HER2-positive tumor on core biopsies. | Baseline and 18 weeks (time frame + 3 weeks) | |
Secondary | Only for those patients randomized for the supportive anemia treatment: Quality of life | To compare quality of life using the FACT-An anemia and fatigue questionnaire between the supportive treatment arms. | up to 18 weeks | |
Secondary | Only for those patients randomized for the supportive anemia treatment: median time to achieve a hemoglobin level =11g/dl | To compare the median time to achieve a hemoglobin level =11g/dl between the supportive treatment arms. | up to 18 weeks | |
Secondary | Only for those patients randomized for the supportive anemia treatment: frequency of patients with a hemoglobin level =11g/dl | To compare the frequency of patients with hemoglobin level =11g/dl in the week after the end of the last chemotherapy cycle between the supportive treatment arms. | up to 18 weeks | |
Secondary | Pharmacogenetic substudy | To correlate Single Nucleotide Polymorphisms (SNPs) of genes with the associated toxicity and histologically assessed treatment effect. | 18 weeks (time frame + 3 weeks) | |
Secondary | GeparPET substudy | To demonstrate that PET-CT before surgery in addition to conventional presurgical staging methods can decrease the mastectomy rate in patients receiving neoadjuvant chemotherapy for breast cancer. | 18 weeks (time frame + 3 weeks) | |
Secondary | Ovarian function | To assess ovarian function measured by amenorrhea rate in correlation with changes in E2, FSH, LH , Anti-Müller Hormone, ultrasound-follicle count in patients aged <45 years. | Baseline until 2 years after EOS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00344071 -
Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
|
N/A | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02221999 -
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02324088 -
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
|
Phase 3 | |
Completed |
NCT00003199 -
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
|
Phase 2 | |
Terminated |
NCT00016276 -
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
|
Phase 3 | |
Recruiting |
NCT01880385 -
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06131632 -
Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
|
N/A | |
Completed |
NCT00513695 -
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
|
Phase 2 | |
Completed |
NCT00340158 -
Establishing an Inflammatory Breast Cancer Registry
|
N/A | |
Recruiting |
NCT04636710 -
Refining Local-Regional Therapy for IBC
|
N/A | |
Active, not recruiting |
NCT05415215 -
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
|
Phase 3 | |
Recruiting |
NCT04030507 -
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT03515798 -
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Completed |
NCT01583426 -
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
|
Phase 3 | |
Recruiting |
NCT02879513 -
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
|
Phase 3 | |
Completed |
NCT02199418 -
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02623972 -
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT00891280 -
Dose-escalation Study of Oral CX-4945
|
Phase 1 | |
Completed |
NCT00049114 -
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
|
Phase 2 |